Cancer Hospital of Yunnan provinceal Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2017
NCT03097848
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Yunnan Cancer Hospital | Yunnan Provincial Cancer Hospital

Active Ingredients

Drugs in Phase 3 Trials (2)

dexamethasone (1 trial)

pomalidomide (pomalyst) (1 trial)

Drugs in Phase 2 Trials (6)

almonertinib (1 trial)

gemcitabine (gemzar) (1 trial)

hs-20089 (1 trial)

paclitaxel (taxol) (1 trial)

sintilimab (1 trial)

tgrx-326 (1 trial)

Drugs in Other Trials (1)

sorafenib (nexavar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Rectal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 9